Dafna Capital Management LLC Uro Gen Pharma Ltd. Transaction History

Dafna Capital Management LLC

$368 Million
Q3 2025

A detailed history of Dafna Capital Management LLC transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Dafna Capital Management LLC holds 27,515 shares of URGN stock, worth $669,439. This represents 0.15% of its overall portfolio holdings.

Number of Shares

27,515

Previous 349,515 92.13%

Holding current value

$669,439

Previous $4.79 Million 88.78%

% of portfolio

0.15%

Previous 1.39%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$12.96 - $21.42 $4.17 Million - $6.9 Million	-322,000 Reduced 92.13%	27,515 $537,000
Q2 2025 Aug 14, 2025	SELL	$3.9 - $15.46 $557,700 - $2.21 Million	-143,000 Reduced 29.03%	349,515 $4.79 Million
Q4 2024 Feb 14, 2025	BUY	$10.52 - $13.11 $353,472 - $440,496	33,600 Added 7.32%	492,515 $5.25 Million
Q3 2024 Nov 14, 2024	SELL	$12.7 - $17.92 $128,079 - $180,723	-10,085 Reduced 2.15%	458,915 $5.83 Million
Q2 2024 Aug 14, 2024	BUY	$12.72 - $19.2 $5.97 Million - $9 Million	469,000 New	469,000 $7.87 Million

Q2 2020 Aug 14, 2020	SELL	$16.5 - $29.7 $39,088 - $70,359	-2,369 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$13.68 - $34.6 $22,134 - $55,982	-1,618 Reduced 40.58%	2,369 $42,000
Q4 2019 Feb 14, 2020	SELL	$21.11 - $34.86 $232,484 - $383,913	-11,013 Reduced 73.42%	3,987 $133,000
Q3 2018 Nov 14, 2018	BUY	$41.65 - $51.7 $208,250 - $258,500	5,000 Added 50.0%	15,000 $708,000
Q2 2018 Aug 13, 2018	BUY	$48.35 - $65.33 $265,925 - $359,315	5,500 Added 122.22%	10,000 $498,000
Q1 2018 May 15, 2018	BUY	$38.64 - $57.54 $173,880 - $258,930	4,500 New	4,500 $224,000

Others Institutions Holding URGN

# of Institutions

171

Shares Held

43.8M

Call Options Held

1.61M

Put Options Held

433K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $553M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.

Account

Dafna Capital Management LLC Uro Gen Pharma Ltd. Transaction History